vitrogro ecm meets ce mark requirements , page-22

The mention of developing other applications and products and the price capping give me the felling a cap raising may be on the cards.

It goes without saying they will be doing ongoing R&D, why make a point of it?

It was said that there was enough money until at least next year but that was before the FDA gave VitroGrow a bio classification. Do they now need more money than originally thought for further R&D and approval?

Also how long will it take to achieve $15 million in sales, which for a 30% net margin to TIS is what’s needed to support a PE of 20. At say $500 per patient, this would be 30000 patients. Seems doable in the next few years but hard to know?